Advanced Drug Delivery Systems: From Precision Targeting to Intelligent Release

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 837

Editor


E-Mail Website
Guest Editor
Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China
Interests: lymph-targeted drug delivery systems; innovative formulations

Special Issue Information

Dear Colleagues,

The convergence of modern pharmaceutics with materials science and biotechnology is driving a paradigm shift in drug delivery, from mere “drug transportation” towards “precision theranostics”. To highlight recent breakthroughs and future perspectives, we cordially invite submissions to this Special Issue. Topics of interest include, but are not limited to, the following: 

  • Targeted Delivery Systems: active and passive targeting strategies for enhanced drug accumulation at disease sites.
  • Site-Specific Release Systems: spatiotemporally controlled systems (e.g., oral colon-specific, gastric retention). 
  • Long-Acting and Sustained-Release Formulations: systems (e.g., microspheres, implants, and nanocrystals) extending therapeutic duration. 
  • Stimuli-Responsive “Smart” Systems: intelligent carriers responding to endogenous (pH, enzymes) or exogenous (temperature, light) signals.

We welcome original research and high-quality reviews that advance the clinical translation of innovative delivery systems. 

Prof. Dr. Shujun Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted delivery
  • site-specific release
  • controlled release
  • stimuli-responsive
  • drug delivery systems

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 2791 KB  
Article
Transdermal Delivery of Sonidegib via Iontophoresis from PEDOT:PSS/Gelatin Hydrogels for Basal Cell Carcinoma Skin Cancer
by Phimchanok Sakunpongpitiporn, Johannes Schwank, Napa Parinyanitikul, Sutima Luangdilok, Nattaya Teeyapun, Aumpika Kesornsit and Anuvat Sirivat
Pharmaceutics 2026, 18(4), 494; https://doi.org/10.3390/pharmaceutics18040494 - 17 Apr 2026
Viewed by 522
Abstract
Background/Objectives: Skin cancers belong to the most frequent cancer type with over a million cases per year. Presently, transdermal drug delivery systems (TDDS) are an attractive drug delivery route, but they still face some limitations due to the resistance of human skin. [...] Read more.
Background/Objectives: Skin cancers belong to the most frequent cancer type with over a million cases per year. Presently, transdermal drug delivery systems (TDDS) are an attractive drug delivery route, but they still face some limitations due to the resistance of human skin. Methods: Here, Sonidegib, PEDOT:PSS, and gelatins were employed as the model drug, drug carrier, and drug matrix, respectively. Results: Gelatin hydrogels were fabricated via the physical crosslinking to avoid toxicity towards the human skin. PEDOT:PSS was synthesized by chemical oxidative polymerization as the drug carrier. Sonidegib first interacted with PEDOT:PSS before they were embedded into the gelatin hydrogels. In the release and release-permeation experiments, the amounts of Sonidegib released and permeated were investigated under the effects of gelatin types, concentrations, pH values, PEDOT:PSS, and electrical voltages. For the effect of gelatin types, the BG gelatin provided higher amounts of Sonidegib release than PG from the higher electrorepulsive force. Under applied electrical voltages and with PEDOT:PSS present, the amounts of Sonidegib release and release-permeation amounts increased as PEDOT:PSS assisted in providing higher electroosmosis and electrorepulsive forces. Conclusions: In summary, PEDOT:PSS in the BG hydrogel is demonstrated here as a potential drug carrier to improve the Sonidegib release and release-permeation iontophoretically for TDDS. Full article
Show Figures

Graphical abstract

Back to TopTop